U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07921420) titled 'MF-300 for Treatment of Age-Related Sarcopenia' on Nov. 02.
Brief Summary: This Phase 2b clinical trial will evaluate whether MF-300 can improve physical function and muscle strength and assess its safety in adults aged 65 years and older with sarcopenia. The study will also evaluate how MF-300 is processed by the body and its effects on measures related to muscle health, quality of life, and physical activity.
Participants will receive MF-300 or placebo once daily for 24 weeks. The study includes an initial open-label part evaluating MF-300 followed by a randomized, placebo-controlled part evaluating two dose levels of MF-300.
Stu...